ANGLE plc

("ANGLE" or "the Company")

Issue of Equity

GUILDFORD, SURREY / ACCESSWIRE / December 23, 2019 / ANGLE plc (AIM:AGL and OTCQX:ANPCY), a world-leading liquid biopsy company, announces that it has received notice from an employee to exercise options over 16,667 ordinary shares of £0.10 each in the Company. Share options were issued to employees pursuant to the arrangements set out in the Company's Share Option Schemes.

Accordingly the Company has issued and allotted 16,667 new ordinary shares of £0.10 each ("New Ordinary Shares") in the capital of the Company. The New Ordinary Shares rank pari passu with the existing ordinary shares in the Company. An application has been made for the New Ordinary Shares to be admitted to trading on AIM and admission is expected to take place at 8:00 am on 30 December 2019. Following this allotment, the total issued share capital of the Company is 172,771,483 ordinary shares.

For further information ANGLE:

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive
Ian Griffiths, Finance Director

finnCap Ltd (NOMAD and Joint Broker)

Corporate Finance – Carl Holmes, Simon Hicks, Max Bullen-Smith
ECM – Alice Lane, Sunila de Silva

+44 (0)20 7220 0500

WG Partners (Joint Broker)

Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee

+44 (0) 203 705 9330

FTI Consulting

Simon Conway, Ciara Martin
Matthew Ventimiglia (US)

+44 (0) 203 727 1000
    +1 (212) 850 5624

For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/

Notes for editors

About ANGLE plc www.angleplc.com

ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.

ANGLE's cell separation technology is called the Parsortix® system, and it enables a liquid biopsy (a simple blood test) to be used to provide the cells of interest to the user in a format suitable for multiple types of downstream analyses. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The system is epitope independent and can capture all types of CTCs as well as CTC clusters in a viable form (alive). CTCs enable the complete picture of a cancer to be seen as being a complete cell they allow DNA, RNA and protein analysis and the live cells harvested can be cultured. The Parsortix technology is the subject of 24 granted patents in Europe, the United States, China, Australia, Canada, India, Japan and Mexico with three extensive families of patents are being progressed worldwide. The Parsortix system has a CE Mark in Europe for the indicated use and FDA clearance is in process for the United States with a 400 subject clinical study and associated analytical studies in metastatic breast cancer. ANGLE is seeking to be the first ever FDA cleared CTC harvesting system and only the third ever FDA cleared liquid biopsy test. ANGLE has already undertaken two separate 200 subject clinical studies under a program designed to develop an ovarian cancer pelvic mass triage test, with the results showing best in class accuracy (ROC-AUC) of 95.1%. The pelvic mass triage assay has undergone further refinement and optimisation, and is currently in the process of a 200 patient clinical verification study.

ANGLE's technology for the multiplex evaluation of proteins and nucleic acids of all types is called the HyCEADTM Ziplex® platform and is based on a patented flow through array technology. It provides for low cost, highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry approach (the HyCEAD method) allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. The HyCEAD Ziplex system is extremely sensitive and is ideal for measuring gene expression and other markers directly from Parsortix harvests and was used in the ovarian cancer pelvic mass triage test to achieve best in class accuracy (ROC-AUC) of 95.1%.

ANGLE's proprietary technologies can be combined to provide automated, sample-to-answer results in both centralised laboratory and point-of-use cartridge formats.

ANGLE has established formal collaborations with world-class cancer centres and major corporates such as Abbott, Philips and QIAGEN, and works closely with leading CTC translational research customers. These Key Opinion Leaders (KOLs) are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. The body of evidence as to the benefits of the Parsortix system is growing rapidly from our own clinical studies in metastatic breast cancer and ovarian cancer and also from KOLs with 26 peer-reviewed publications and numerous publicly available posters, available on our website.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc

ReleaseID: 571158

Data from more than 2,000 patients enrolled in the FROG-ICU study demonstrate that high levels of bioactive adrenomedullin (bio-ADM(R)) predict the need for organ support, ionotropes, and vasopressors in the general patient population at admission to the intensive care unit (ICU).
bio-ADM(R) screening of patients admitted for septic or non-septic reasons supports stratification of risk patients that need immediate therapeutic intervention due to an elevated risk of organ failure.
sphingotec will launch a CE-marked IVD point-of-care assay for bio-ADM(R) rapid testing on its proprietary Nexus IB10 immunoassay platform in mid-2020.

HENNIGSDORF/BERLIN, Germany / ACCESSWIRE / December 23, 2019 / Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf, Germany) today announced a publication in Critical Care1 with data on 2,000 ICU patientsdemonstrating that sphingotec's proprietary biomarker bio-ADM(R) (Bioactive Adrenomedullin) not only identifies high-risk patients for septic shock at admission but also identifies patients in the general ICU patient population who require immediate life-saving therapeutic intervention.

In an observational ancillary study to the FROG-ICU study, high blood levels of bio-ADM(R) at admission to the ICU were an early predictor of the requirement for organ support and treatment with ionotropes and vasopressors. Elevated bio-ADM(R) blood levels were also significantly associated with a prolonged length of ICU stay and fatal outcomes within 28 days post-admission, whereas low levels of bio-ADM(R) at admission were associated with positive outcomes.

This study is the largest published investigation on bio-ADM(R) in a patient cohort of which about 25% of patients suffered from sepsis and 75% of patients had conditions that were not sepsis-related. According to principal investigator Prof. Alexandre Mebazaa (Hôpital Lariboisière, Paris, France), the results demonstrate that bio-ADM(R) is not only a biomarker indicating impaired endothelial function in patients with septic shock as previously shown2, but also identifies further ICU patients who require rapid therapeutic intervention at admission due to distortion in endothelial function, which is independently associated with malperfusion of organs.

Previous data from more than 20,000 patients provide evidence, that high blood levels of bio-ADM(R) reflect impaired endothelial function independently from inflammation and other co-morbidities. High bio-ADM(R) blood levels indicate distortions in the barrier function of the endothelium before the patients progress to a critical stage. Failure of endothelial function has been demonstrated to precede the life-threatening blood pressure drop that causes shock and multiorgan failure e.g. in patients with sepsis at ICUs and in emergency departments (EDs) 2-3. Each year, 6 million people die from sepsis, one of the largest contributors to global disease burden causing $24 billion in direct annual costs to the U.S. healthcare system alone. As elevated bio-ADM(R) blood levels precede septic shock, bio-ADM(R) screening can identify risk patients who require early life-saving therapeutic intervention.

"The new study results add data to the broad body of existing evidence that our biomarker bio-ADM(R) can reliably support critical care physicians in identifying high-risk patients when they first present at the ICU," said Dr. Andreas Bergmann, founder and CEO of sphingotec. "We are set to launch the fully automated CE-IVD-marked point-of-care bio-ADM(R) assay on our widely established Nexus IB10 immunoassay platform by mid-2020. We are convinced that this rapid test for bio-ADM(R) will support earlier treatment decisions and improve outcomes of patients at ICUs and emergency departments."

Lemasle L. et al., (2018): Bioactive Adrenomedullin, Organ Support Therapies, and Survival in the Critically Ill: Results from the French and European Outcome Registry in ICU Study. Crit Care Med. doi: 10.1097/CCM.0000000000004044
Mebazaa A. et al., (2018): Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock (AdrenOSS-1) study. doi:10.1186/s13054-018-2243-2
Geven C. et al., (2018): Vascular Effects of Adrenomedullin and the anti-Adrenomedullin Antibody Adrecizumab in Sepsis. Shock. doi: 10.1097/SHK.0000000000001103

###

About bio-ADM(R)

As a marker of endothelial function, bioactive Adrenomedullin (bio-ADM(R)) enables both prediction of circulatory shock before blood pressure decline, e.g. in septic patients, and diagnosis of residual congestion in acute heart failure patients. Data from more than 20,000 patients provide evidence, that high plasma levels of bio-ADM(R) reflect impaired endothelial function independently from inflammation and other co-morbidities. High bio-ADM(R) plasma levels indicate distortions in the barrier function of the endothelium before the patients progress to a critical stage. Failure of endothelial function has been demonstrated to precede the life-threatening blood pressure drop that causes shock and multiorgan failure e.g. in patients with sepsis at ICUs and in emergency departments (EDs). As elevated bio-ADM(R) plasma levels precede septic shock, bio-ADM(R) screening can identify risk patients who require early life-saving therapeutic intervention.

About sphingotec

SphingoTec GmbH ("sphingotec"; Hennigsdorf near Berlin, Germany) develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as sepsis, acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies. sphingotec's proprietary biomarker portfolio includes bioactive adrenomedullin (bio-ADM(R)), a unique biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, Proenkephalin (penKid(R)), a unique biomarker for real-time assessment of kidney function, and Dipeptidyl Peptidase 3 (DPP3), a unique biomarker for cardio-renal pathway disruptions leading to acute organ dysfunction. In addition, sphingotec develops a portfolio of novel biomarkers, which predict the risks of developing obesity, breast cancer and cardiovascular diseases. IVD tests for sphingotec's proprietary biomarkers are made available as sphingotest(R) microtiterplate tests as well as point-of-care tests on the Nexus IB10 immunoassay platform by sphingotec's subsidiary Nexus Dx Inc. (San Diego, CA, USA) alongside a broad menu of IB10 tests for established biomarkers for acute and critical care.

About Nexus Dx Inc. and the IB10 Platform

Nexus Dx Inc., a wholly-owned subsidiary of sphingotec, headquartered in San Diego, CA, USA, is a global provider of a near patient testing system and advanced diagnostic solution. The company is improving patient care by providing the medical community with rapid and reliable information at the point of care (POC), delivering patient information when and where it is needed most. The company has invested over $160m to develop and market the IB10 analyzer system which, without the need for sample preparation, automatically separates plasma from whole blood with subsequent reliable and quantitative detection of biomarkers in the plasma by means of antibodies. With a hands-on-time of less than 3 minutes the easy-to-use system provides in only 20 minutes test results for biomarkers that are crucial in the management of critical care patients. The portfolio of IB10 assays includes tests for established critical care parameters such as Procalcitonin, Troponin I, CK-MB, Myoglobin, NT-proBNP, and D-Dimer as well as tests for sphingotec's proprietary biomarkers such as DPP3, an assay for Dipeptidyl Peptidase 3, a unique and proprietary biomarker for cardio-renal pathway disruptions leading to acute organ dysfunction. The IB10 assay for bioactive Adrenomedullin (bio-ADM(R)), a unique and proprietary biomarker for endothelial function and the assay for Proenkephalin (penKid(R)), a unique and proprietary biomarker for real-time assessment of kidney function, will be launched later in 2020.

Contact
SphingoTec GmbH
Ruxandra Lenz
PR & Market Communications Manager

Neuendorfstr. 15A
16761 Hennigsdorf
Germany

Tel. +49-3302-20565-34
press@sphingotec.de
www.sphingotec.com

SOURCE: SphingoTec GmbH

ReleaseID: 571157

SAN FRANCISCO, CA / ACCESSWIRE / December 23, 2019 /  Hagens Berman alerts iRobot Corporation (NASDAQ:IRBT) investors of today's deadline to move for lead plaintiff in a securities fraud class action pending against the Company and urges IRBT investors who have suffered losses to contact the firm immediately.

Class Period: Nov. 21, 2016 – Oct. 22, 2019

Lead Plaintiff Deadline: Dec. 23, 2019

Sign Up Now: www.hbsslaw.com/investor-fraud/IRBT

Contact An Attorney Immediately: IRBT@hbsslaw.com

844-916-0895

iRobot Corporation (IRBT) Securities Class Action:

The Complaint alleges that, throughout the Class Period, iRobot reported explosive, double-digit revenue growth, which it attributed to increasing demand for its Roomba products, expanded gross margin due to distributor acquisitions, greater brand awareness and technological innovation. In reality, iRobot was engaging in channel-stuffing in order to inflate its sales and revenues figures, and had acquired two of its largest distributors in order to facilitate and conceal this deceptive practice. As a result of these misrepresentations, iRobot shares traded at artificially inflated prices throughout the Class Period.

The market learned the truth about iRobot's fraud through a series of disclosures between April 23, 2019 and October 22, 2019, when the Company, unable to continue its channel-stuffing scheme, announced disappointing quarterly revenues and poor financial guidance. All told, these disclosures caused iRobot shares to decline precipitously, wiping out significant shareholder value.

"We're focused on investors' losses and whether the company inflated its reported revenues," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you purchased shares of IRBT and suffered significant losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding iRobot should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email IRBT@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 844-916-0895

SOURCE: Hagens Berman Sobol Shapiro LLP

ReleaseID: 571033

SAN FRANCISCO, CA / ACCESSWIRE / December 23, 2019 / Hagens Berman alerts Infosys Limited (NYSE: INFY) investors of today's deadline to move for lead plaintiff in a securities fraud class action pending against the Company and urges INFY investors who have suffered losses to contact the firm immediately.

Class Period: July 7, 2018 – Oct. 20, 2019

Lead Plaintiff Deadline: Dec. 23, 2019

Sigh Up Now: www.hbsslaw.com/investor-fraud/INFY

Contact An Attorney Immediately: INFY@hbsslaw.com

844-916-0895

Infosys Limited (INFY) Securities Class Action:

The Complaint alleges Defendants misstated Infosys's true revenues by engaging in improper revenue recognition practices. The Complaint further alleges that the CEO evaded reviews and approvals of large deals to avoid accounting scrutiny, and that management pressured the Company's finance team to conceal information from auditors and the Board of Directors.

On October 21, 2019, Reuters reported the Company received whistleblower complaints alleging "unethical practices" by certain executives to boost short-term revenue and profits, in violation of generally accepted accounting principles.

This news drove the price of INFY shares sharply lower during intraday trading on October 21, 2019.

"We are focused on investors' losses and whether Infosys's senior management cooked the books," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you purchased shares of INFY and suffered significant losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Infosys should consider their options to help in the investigation or take advantage of the SEC whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email INFY@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 844-916-0895

SOURCE: Hagens Berman Sobol Shapiro LLP

ReleaseID: 571030

SAN FRANCISCO, CA / ACCESSWIRE / December 23, 2019 /  Hagens Berman alerts Pareteum Corp. (NASDAQ:TEUM) investors of today's deadline to move for lead plaintiff in a securities fraud class action pending against the Company and urges TEUM investors who have suffered losses to contact the firm immediately.

Most Expansive Class Period: Dec. 14, 2017 – Oct. 21, 2019

Lead Plaintiff Deadline: Dec. 23, 2019

Sign Up Now: www.hbsslaw.com/investor-fraud/TEUM

Contact An Attorney Immediately: TEUM@hbsslaw.com

844-916-0895

Hagens Berman's Pareteum Corp. (TEUM) Securities Class Action:

Hagens Berman filed an expansive Complaint on behalf of all investors who purchased or otherwise acquired Pareteum Corporation securities and pursues claims against the Defendants under the Securities Exchange Act of 1934 (the "Exchange Act"). After Hagens Berman filed its Complaint, other substantially similar complaints have been filed alleging differing class periods. To date, the most expansive class Period is Dec. 14, 2017 through Oct. 21, 2019, inclusive.

According to the detailed Complaint filed by Hagens Berman, Defendants misled investors by materially misrepresenting Pareteum's true business operations and financial results.

Specifically, the Complaint alleges Defendants misrepresented Pareteum as a "rapidly growing Cloud Communications Platform company" that was poised for exponential growth due to the Company's involvement in new industries such as block chain, customer wins, a rising "36-month contract revenue backlog," and effective contract conversion rates when in truth none of that was true.

The Complaint alleges, unbeknownst to investors and contrary to Defendants' statements, Pareteum contracted with either fake entities, related-third parties, or companies so small they had no chance of ever satisfying the value Defendants assigned to their contracts. Moreover, throughout the Expanded Class Period, Defendants violated Generally Accepted Accounting Principles ("GAAP") by prematurely recognizing revenues and inflating accounts receivable.

The truth emerged through a series of disclosures occurring between June 7, 2019 and October 21, 2019, when the Company announced that it will restate its consolidated financial statements as of and for the full year ended December 31, 2018, and interim periods ended March 31, 2019 and June 30, 2019 (the "Non-Reliance Periods").

As a result of these disclosures, the value of Pareteum stock has consistently decreased, damaging investors.

On Nov. 15, 2019, after announcing the company would not timely file its quarterly financial statements as a result of its plan to restate financial statements for the Non-Reliance Periods, Pareteum disclosed that it had received a notice from Nasdaq stating the company was not in compliance with its rules and is in danger of being delisted.

On Nov. 25, 2019, Defendants announced Robert H. Turner has been terminated as Chairman and CEO of Pareteum.

"We're focused on recovering investors' substantial losses and holding Pareteum and its senior management accountable for their outright fraud," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you purchased shares of TEUM and suffered significant losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Pareteum should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email TEUM@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 844-916-0895

SOURCE: Hagens Berman Sobol Shapiro LLP

ReleaseID: 571026